1-12 of 12
Authors: Marjolein de Bruin-Weller
Journal Article
680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.054, https://doi.org/10.1093/bjd/ljae266.054
Published: 08 August 2024
Journal Article
684 - Amlitelimab (an anti-OX40 ligand antibody) vs placebo in patients with moderate-to-severe atopic dermatitis: study design of phase 3 OCEANA clinical trials COAST 1/2, SHORE, AQUA, and ESTUARY Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.058, https://doi.org/10.1093/bjd/ljae266.058
Published: 08 August 2024
Journal Article
695 - Long-term dupilumab treatment is not associated with an increased overall risk of infections in adults with moderate-to-severe atopic dermatitis Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.069, https://doi.org/10.1093/bjd/ljae266.069
Published: 08 August 2024
Journal Article
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage) Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.005, https://doi.org/10.1093/bjd/ljae266.005
Published: 08 August 2024
Journal Article
718 - Dupilumab reduces the number of lesions in adult patients with prurigo nodularis presenting with multiple lesion morphologies: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2) Get access
British Journal of Dermatology, Volume 191, Issue Supplement_2, August 2024, ljae266.091, https://doi.org/10.1093/bjd/ljae266.091
Published: 08 August 2024
Journal Article
The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis Get access
British Journal of Dermatology, Volume 191, Issue 3, September 2024, Pages 316–317, https://doi.org/10.1093/bjd/ljae174
Published: 25 April 2024
Journal Article
529 - Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial Get access
British Journal of Dermatology, Volume 190, Issue Supplement_2, February 2024, Pages ii31–ii32, https://doi.org/10.1093/bjd/ljad498.034
Published: 07 February 2024
Journal Article
526 - Efficacy of upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis: analysis of time spent in itch response state from the Heads Up study Get access
British Journal of Dermatology, Volume 190, Issue Supplement_2, February 2024, Pages ii28–ii29, https://doi.org/10.1093/bjd/ljad498.031
Published: 07 February 2024
Journal Article
496 - Conjunctivitis does not increase with longer duration of lebrikizumab exposure in patients with moderate-to-severe atopic dermatitis Get access
British Journal of Dermatology, Volume 190, Issue Supplement_2, February 2024, Pages ii5–ii6, https://doi.org/10.1093/bjd/ljad498.007
Published: 07 February 2024
Journal Article
373 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials Get access
British Journal of Dermatology, Volume 188, Issue Supplement_3, June 2023, ljad162.004, https://doi.org/10.1093/bjd/ljad162.004
Published: 20 June 2023
Journal Article
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest Get access
British Journal of Dermatology, Volume 188, Issue Supplement_2, February 2023, ljac140.009, https://doi.org/10.1093/bjd/ljac140.009
Published: 25 January 2023
Journal Article
Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials Open Access
British Journal of Dermatology, Volume 187, Issue 6, 1 December 2022, Pages 888–899, https://doi.org/10.1111/bjd.21867
Published: 01 December 2022
